Pipeline

« Back to Pipeline

Sorrento’s R&D is focused on driving innovation in COVID-19, cancer treatment, full pain control and autoimmune diseases

Portfolio Key Programs Indication Preclinical Phase I Phase II Phase III/Pivotal FDA Approval
COVID-19 Programs

COVI-TRACE™ (diagnostic) Diagnostic Test

0%*

FDA Emergency Use Authorization (EUA) Application Expected

COVI-STIX™ (diagnostic) Antigen Test

0%*

FDA Emergency Use Authorization (EUA) Application Submitted

COVI-TRACK™ – Platinum (diagnostic) Next Generation Antibody Test

0%*

In final manufacturing and clinical testing

COVI-GUARD™ (treatment) Neutralizing Antibody (IV) in Inpatients

30%*

COVI-AMG™ (treatment) Neutralizing Antibody (IV) in Outpatients

30%*

COVI-DROPS™ (treatment) Neutralizing Antibody (Intranasal) in Outpatients

10%*

COVI-SHIELD™ (treatment) Neutralizing Abs (IV) in Inpatients

10%*

COVIDTRAP™ (treatment) ACE2 Receptor Decoy (IV) in Inpatients

10%*

ABIVERTINIB (treatment) Severe or Critical COVID-19 in ICU Patients

55%*

SALICYN – 30 (treatment) Anti-viral

10%*

COVI-MSC (treatment) ARDS due to COVID-19 in ICU Pts

30%*

Immunotherapy

CD38 CAR-T Multiple Myeloma

30%*

CD38 DAR-T Multiple Myeloma

10%*

CD38 ADC Amyloidosis

30%*

Seprehvir™ Solid Tumors

30%*

Seprehvec™ Solid Tumors

30%*

ABIVERTINIB NSCLC

80%*

ADNIC Solid and Liquid Tumors

55%*

Pain

RTX (resiniferatoxin)
Epidural route
Intractable Pain in Advanced Cancer

55%*

Orphan designation

RTX (resiniferatoxin)
Intra-articular route
Moderate to Severe OA

55%*

Lymphatic Delivery

Sofusa® anti-TNF Autoimmune

30%*

Sofusa® anti-PD-1 CTCL

30%*

COVID-19 Programs
Key Programs (Indication) Phase
COVI-TRACE™ (diagnostic) FDA EUA
COVI-STIX™ (diagnostic) FDA EUA
COVI-TRACK™ – Platinum (diagnostic) FDA EUA
COVI-GUARD™ (treatment) Ph I
COVI-AMG™ (treatment) Ph I
COVI-DROPS™ (treatment) Preclinical
COVI-SHIELD™ (treatment) Preclinical
COVIDTRAP™ (treatment) Preclinical
ABIVERTINIB (treatment) Ph II
SALICYN – 30 (treatment) Preclinical
COVI-MSC (treatment) Ph I
Immunotherapy
Key Programs (Indication) Phase
CD38 CAR-T (Multiple Myeloma) Ph I
CD38 DAR-T (Multiple Myeloma) Preclinical
CD38 ADC (Amyloidosis) Ph I
Seprehvir™ (Solid Tumors) Ph I
Seprehvec™ (Solid Tumors) Ph I
ABIVERTINIB (NSCLC) PhIII/Pivotal
ADNIC (Solid and Liquid Tumors) Ph II
Pain
Key Programs (Indication) Phase
RTX (resiniferatoxin) Epidural route (Terminal Cancer Pain) Ph II
RTX (resiniferatoxin) Intra-articular route (Moderate to Severe OA) Ph II
Lymphatic Delivery
Key Programs (Indication) Phase
Sofusa® anti-TNF (Autoimmune) Ph I
Sofusa® anti-PD-1 (Immuno Oncology) Ph I